二月的广西，草木蔓发，春山可望。在这生机勃发的美好时节，来自全区各地、各条战线的人大代 表肩负人民重托，齐聚一堂，共商"十五五"发展大计，共绘新时代壮美广西宏伟蓝图。我们向自治区十 四届人大五次会议开幕表示热烈的祝贺！ 回望2025，这是"十四五"规划收官之年，也是广西砥砺奋进、攻坚克难、积厚成势的一年。在自治 区党委团结带领下，全区上下坚持实干为要、创新为魂，用业绩说话、让人民评价，全力以赴拼经济、 惠民生、净生态、转作风，推动经济社会发展呈现稳中有进、稳中向新、稳中提质的良好态势。 这一年，经济运行持续向好。地区生产总值同比增长5.1%，增速实现高于预期目标、高于上年同 期、高于全国"三个高于"，交出了一份厚重提气的成绩单。 过去一年，自治区人大常委会坚持党的领导、人民当家作主、依法治国有机统一，紧扣自治区党委 决策部署，聚焦高质量发展主题，依法履职、主动作为。提请自治区十四届人大三次会议审议通过平陆 运河保护与管理条例，为国家重大工程提供法治保障；加强人工智能治理立法研究，前瞻布局新兴领域 制度供给；制定全国首件地方特色优势品种茶叶发展省级地方性法规——六堡茶发展条例，以良法善治 赋能特色产业发展……全 ...

同样依托农业优势转型升级的王守义十三香，在智能化生产车间里上演着"老手艺"的"新玩法"。从原料 处理到成品包装，全流程自动化运作，机械臂与传送带默契配合，全力应对春季销售旺季。"我们紧跟 健康消费趋势，加大研发投入开发低盐、复合香型产品，靠数据分析和精准调控赋能传统秘方。"公司 相关负责人的话语中透着自信。 隆冬时节，乍寒还暖。豫南平原的麦苗在暖阳中舒展腰肢，而驻马店星罗棋布的工业园区内，另一 股"生长"力量更为炽热——生产线高速运转，机器轰鸣声奏响发展强音。 驻马店，这个长期以"中原粮仓"闻名的农业大市，近几年大力推进制造强市建设，坚持把制造业高质量 发展作为主攻方向，把发展经济的着力点放在实体经济上，完成从"产粮大市"到"制造强市"的精彩跨 越，在黄淮平原上勾勒出一幅多元协同、动能充沛的产业升级画卷。 立足"农头"延伸价值链，传统产业焕发新生机。1月11日，在驻马店经济开发区的金玉锋大健康产业 园，数十米高的生物反应罐巍然矗立，来自本地及周边的玉米，经过净化、破碎、发酵等精密工序， 被"吃干榨净"后转化为结晶葡萄糖、赖氨酸等高附加值产品。"一期6个项目满负荷运转，产能利用率连 续多月保持95%以上。"该公 ...

北京经开区相关负责人透露，"十四五"期间，亦庄新一代信息技术、高端汽车和新能源智能汽车、生物 技术和大健康、机器人和智能制造等主导产业年均增长8%，未来产业规模以上企业数量占全市四分之 一，形成了6个千亿级产业集群，以北京1.37%的土地贡献了近四成的工业增加值。 现代化产业体系全面成势，带来区域综合经济实力大幅跃升。初步统计，北京经开区在"十四五"时期的 经济总量保持年均10%高速增长，居头部国家级经开区首位。固定资产投资连续3年保持千亿规模，实 际利用外资跻身全市前列。从经济综合实力来看，北京经开区始终保持在国家级经开区第一梯队。2025 年，北京经开区地区生产总值预计增长9%左右，工业总产值预计增长11%左右，对全市产值增长贡献 率超50%，占比全市第一。 超千项"三城"科技成果落地 2021年，北京集成电路产教融合基地启动。这一基地的"产"是经开区的集成电路产业，"教"是北京大 学、清华大学、中科院微电子所的"强强联合"。近年来，基地的多个结题项目直接解决了先进制程工 艺、关键装备材料等领域的技术难题，还培养了约600名硕博研究生，九成进入集成电路行业。 本报记者 曹政 近日，北京经开区"亮"出"十四 ...

Core Viewpoint - The Wuhan Municipal Committee's 14th Plenary Session established the goal of fully building a modernized Wuhan by creating "Five Centers" and outlined a development blueprint for the next five years [1][32]. Group 1: Five Centers and Industry Development - The term "Five Grains" symbolizes the concentrated development of high-end industries in Wuhan, including Optics Valley, Auto Valley, Aerospace Valley, Cyber Valley, and Pharmaceutical Valley, which are essential for the city's industrial growth [2]. - The "Five Grains" initiative aims to promote the interconnected development of these specialized industrial clusters, enhancing Wuhan's growth trajectory [2]. - The expected industry scale for the Cyber Valley is projected to reach 25 billion yuan this year, focusing on a comprehensive cybersecurity industry chain [5]. - The Aerospace Valley, as China's first national commercial aerospace base, anticipates an industry scale exceeding 100 billion yuan this year, with significant advancements in satellite production and launch frequency [6]. - The Auto Valley is expected to achieve a scale of 500 billion yuan this year, emphasizing the transition from traditional fuel vehicles to new energy vehicles [7]. - The Pharmaceutical Valley is projected to reach an industry scale of 660 billion yuan this year, focusing on medical innovation and the development of new drugs [8]. Group 2: Urban Renewal and Innovation - The city plans to implement a "Five Reforms and Four Goods" strategy over the next five years, focusing on urban function renewal, industrial revitalization, and governance innovation [18]. - Key urban renewal efforts will include the renovation of unsafe housing, old neighborhoods, and industrial areas, aiming to improve living conditions and activate historical spaces [21][20]. - The initiative aims to transform old residential areas into complete communities, with a target of 40% of communities being fully developed by the end of the year [21]. Group 3: Transportation and Regional Integration - The extension of Wuhan Metro Line 11 to Gedian South Station exemplifies the integration of urban and suburban areas, facilitating a half-hour commute between Wuhan and neighboring cities [27]. - The city is focusing on strengthening its core, expanding its urban circle, and promoting collaborative development within the Yangtze River middle reaches urban cluster [28].

Core Viewpoint - The company emphasizes the importance of innovation in drug development for oncology, autoimmune diseases, and neurobiology, highlighting unmet clinical needs and significant market demand in these areas [1] Group 1: Oncology - Oncology remains a key focus for innovative drug development, with ongoing clinical demand for breakthroughs in immunotherapy, targeted therapy, and personalized medicine due to increasing drug resistance [1] Group 2: Autoimmune Diseases - Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are critical areas of interest for biopharmaceutical companies, particularly as they affect the younger workforce and have lower treatment efficacy and adherence [1] Group 3: Neurobiology - Neurodegenerative diseases like Alzheimer's, Parkinson's, and diabetic neuropathy are gaining significant attention from global pharmaceutical companies and research institutions, driven by the rapid increase in patient numbers due to global aging [1] Group 4: Company Pipeline - The company has established multiple self-developed drug pipelines in neurobiology, autoimmune diseases, and oncology, having obtained three IND approvals for Class I new drugs and ten IND approvals for Class II new drugs [1]

Core Viewpoint - The company emphasizes the importance of innovation in drug development for oncology, autoimmune diseases, and neurobiology, highlighting unmet clinical needs and market demand in these areas [1] Group 1: Oncology - Oncology remains a key focus in innovative drug development, with increasing resistance leading to ongoing breakthroughs in immunotherapy, targeted therapy, and personalized medicine [1] - There is a persistent unmet clinical demand in the oncology sector, indicating potential investment opportunities [1] Group 2: Autoimmune Diseases - Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are significant areas of interest for biopharmaceutical companies [1] - These diseases predominantly affect the younger workforce, and there is a high demand for effective treatments due to poor treatment outcomes and medication adherence [1] Group 3: Neurobiology - Neurodegenerative diseases like Alzheimer's, Parkinson's, and diabetic neuropathy are gaining attention from global pharmaceutical companies and research institutions [1] - The aging global population is contributing to a rapid increase in the number of patients with neurodegenerative diseases, creating substantial market demand [1] Group 4: Company Performance - For the period from January to September 2025, the company reported revenue of 510 million yuan, a year-on-year decrease of 29.33% [1] - The net profit attributable to the parent company was 6 million yuan, reflecting a significant year-on-year decline of 95.68% [1] Group 5: Drug Development Pipeline - The company has established multiple self-developed drug pipelines in neurobiology, autoimmune diseases, and oncology [1] - It has obtained three IND approvals for Class I new drugs and ten IND approvals for Class II new drugs, indicating progress in its drug development efforts [1]

Core Insights - The Pudong New Area is enhancing the integration of technology and industry, focusing on three leading sectors: integrated circuits, biomedicine, and artificial intelligence [1] Integrated Circuits - From January to September this year, the Pudong New Area exported electronic components worth $20.6 billion in the integrated circuit sector, marking a year-on-year growth of 7.4% [1] - The resilience of the integrated circuit industry chain in Pudong has improved, achieving self-sufficiency across the entire chain from design to manufacturing, packaging, testing, equipment, materials, and EDA software, with a total scale reaching $41 billion [1] Biomedicine - Pudong has attracted over 4,000 enterprises in the biomedicine sector [1] - This year, Pudong has approved four CAR-T products and seven Class I new drugs, with the business development transaction amount for innovative drugs reaching $20.4 billion [1] Artificial Intelligence - The Zhangjiang Moli community in Pudong has gathered over 150 specialized large model enterprises within 14 months [1] - Pudong has opened over 1,000 kilometers of high-level autonomous driving testing roads and established a 6G outdoor testing environment, accelerating the ecosystem for new tracks such as synthetic biology, satellite internet, and new energy storage [1]

Core Insights - The Pudong New Area is enhancing the integration of technology and industry, focusing on three leading sectors: integrated circuits, biomedicine, and artificial intelligence [1] Integrated Circuits - From January to September this year, the integrated circuit industry in Pudong reported electronic component exports of $20.6 billion, reflecting a year-on-year growth of 7.4%, contributing to global supply chain stability [1] - The resilience of the integrated circuit industry chain in Pudong has improved, achieving self-sufficiency across the entire chain from design to manufacturing, packaging, testing, equipment, materials, and EDA software, with a total scale reaching $41 billion [1] Biomedicine - Pudong has attracted over 4,000 enterprises in the biomedicine sector, with approvals for 4 CAR-T products and 7 Class I new drugs this year, leading to a business development transaction amount of $20.4 billion for innovative drugs [1] Artificial Intelligence - In the artificial intelligence sector, the Zhangjiang Moli community has gathered over 150 specialized large model enterprises within 14 months [1] - Pudong has opened over 1,000 kilometers of high-level autonomous driving testing roads and established a 6G outdoor testing environment, accelerating the ecosystem development in new areas such as synthetic biology, satellite internet, and new energy storage [1]

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference was held in Nanjing on October 26-27, highlighting advancements in China's drug development landscape [1] - The new phase of the "National Major Special Project for Innovative Drug Development" has been launched this year, building on the previous round of initiatives and achieving leapfrog development [1][2] - Significant breakthroughs have been made in major drug development, with 84 new class drugs approved, a substantial increase compared to prior to the implementation of related projects [1] Group 1 - The transition from a focus on imitation to independent creation in drug development has been fundamentally altered by the "Major New Drug Creation Major Special Project" from 2008 to 2020 [1] - China has gained strong international influence in specific fields such as Antibody-Drug Conjugates (ADC) and cell therapy [1] - The innovation capabilities of domestic companies have significantly improved, with some original drugs developed by local firms receiving FDA approval [1] Group 2 - The strategic planning for the new phase of the national drug development project emphasizes leveraging past experiences while targeting new high-peak areas [2] - The project aims to shift from single product development to a three-pronged approach focusing on products, talent, and platforms to enhance research capabilities [2] - The initiative will also focus on upstream innovation, addressing unmet clinical needs, and promoting forward-looking innovative approaches [2] Group 3 - The main tasks of the project will revolve around drug research connections, including new drug target discovery and traditional Chinese medicine development [3] - By 2035, the goal is to establish a self-controlled, efficient, and robust national drug innovation system, positioning China as a global center for new drug creation and biopharmaceutical industry [3]

Core Viewpoint - The 2025 Pudong New Area Science and Technology Festival emphasizes the integration of industry, scientific innovation, and popular science, showcasing Pudong's advancements in technology and innovation to a global audience [1][4]. Group 1: Event Overview - The festival features an opening ceremony, over 10 key popular science activities, and more than a thousand grassroots science activities, aiming to engage various age groups and promote scientific knowledge [1]. - The event aims to present Pudong's breakthroughs in technology innovation, open ecosystem construction, and talent cultivation [1]. Group 2: Technological Achievements - Pudong has established 3 national laboratories and 14 major scientific facilities, achieving significant original innovations in fields like quantum computing [4]. - Key industries in Pudong, such as aerospace with the C919 aircraft and high-end manufacturing with the "Aida·Magic City" cruise, demonstrate strong growth potential [4]. - The region has over 5,000 high-tech enterprises and 51 companies listed on the Sci-Tech Innovation Board, with technology contract transaction volume exceeding 1 trillion yuan [4]. Group 3: Talent Development - The festival highlights the importance of nurturing young talent in driving technological innovation and new productivity [5]. - Initiatives like the "Support for Young Talent Innovation and Entrepreneurship" program provide a supportive environment for young entrepreneurs in areas like Zhangjiang and Jinqiao [5]. Group 4: Open Innovation Initiatives - The Global Open Innovation (GOI) initiative has expanded, with new international companies joining, enhancing Pudong's innovation ecosystem [6]. - The GOI has facilitated technological breakthroughs for 3,600 companies and attracted over 5.4 billion yuan in investments, establishing Pudong as a global innovation hub [6]. Group 5: Science Popularization Activities - The festival will include over a thousand activities aimed at increasing public engagement with science, such as the "Beidou Satellite Revealed" lectures and various community events [7]. - Key activities will focus on youth science festivals, farmer technology festivals, and health science series, promoting the message of "technology changing lives" [7].